Articles On Neuren Pharmaceuticals (ASX:NEU)

Highlights Australian health companies reported progress across diagnostics, therapeutics, and clinical development Research milestones and regulatory updates shaped quarterly activity in the healthcare space ASX-listed heal...

The a2 Milk Company Ltd (ASX: A2M) shares have fallen 11% after the company responded to an ASX price query, confirming no undisclosed material information. Management pointed to an external market announcement as a context for the volatili...

The Region Group Ltd (ASX: RGN) share price is in focus today after the company announced a leadership transition, naming Greg Chubb as its new Chief Executive Officer and Managing Director, starting 9 March 2026. Outgoing CEO Anthony Mello...

The A2 Milk Company Ltd (ASX: A2M) share price has been temporarily paused on the ASX pending a further announcement. Investors are watching closely after the company's latest trading halt was declared today. What did The A2 Milk Company re...

The Nickel Industries Ltd (ASX: NIC) share price is in focus today after the miner reported December quarter adjusted EBITDA from operations is expected to be between US$35 million and US$40 million, with record quarterly earnings from its...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is in focus following the release of new guidance, with DAYBUE global net sales now projected to reach around US$700 million in 2028. The company highlighted that these royalties and mil...

Shares in ALS Ltd (ASX: ALQ) finished last week on a strong note, closing up 1.88% at $23.86. Earlier in Friday's session, the ALS share price also hit a fresh all-time high of $23.91, marking another milestone in what has been an impres...

ASX health sector up 0.96% for the week, while broader market rises 2% Imricor surges after receiving FDA 510(k) clearance for its Vision MR Diagnostic Catheter Morgans upgrades 12-month target price for EBR systems after strong Q4 CY25 re...

Highlights Global banking and technology trends set the tone for local trade Mining and utilities reflect mixed sentiment across sectors Corporate updates offer insight into operational strategies The ASX session unfol...

Healthcare was the worst performer of the 11 market sectors in 2025, with the S&P/ASX 200 Healthcare Index (ASX: XHJ) falling 24.91%. The typically small dividend paid by healthcare shares offset this only slightly, with the sector's...

The S&P/ASX 200 Index (ASX: XJO) enjoyed another green day this Wednesday, its third of the week, as investors gained optimism about the state of the markets. By the time trading wrapped up today, the A...

Good Afternoon and welcome to HotCopper’s Market Close for Wednesday, I’m Jon Davidson. Yesterday I noted the energy sector led laggards despite higher oil prices, well today the market woke up. Prices are currently fetching US$65/bbl, and...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has given back its morning gains and slipped into the red. At the time of writing, the benchmark index is down 0.2% to 8,789.6 points. Four ASX shares that are not letting that hold...

An ASX healthcare stock is back in focus today after a fresh update lifted confidence in its long-term outlook. The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is up 7.77% to $20.80. Over the past year, the stock has climbed a...

Highlights Resource shares draw early attention Corporate updates influence sector movement Global trends shape local sentiment Australian equities opened cautiously as global cues remained mixed. Resource companies ga...

There are a lot of ASX growth shares out there for investors to choose from. To narrow things down, let's take a look at five that brokers rate as buys. Here's what you need to know about them: Aristocrat Leisure Ltd (ASX: ALL) Aristocrat...

The S&P/ASX 200 Index (ASX: XJO) produced a total return of 10.32% last year. That was comprised of 6.8% capital growth and 3.52% dividends. That dividend yield is below the benchmark index's historical average of 4.5% per annum s...

S&P/ASX 200 Index (ASX: XJO) shares rose by 6.8% and provided total gross returns, including dividends, of 10.32% in 2025. The benchmark index hit a record 9,115.2 points in October before finishing the year at 8,714.31 points. Th...

Betashares Australian Quality ETF (ASX: AQLT) has returned an average 12.5% per year to investors since its inception in April 2022. AQLT does things a little differently to standard index-tracking exchange-traded funds (ETFs). Inste...

In a tight race, drug developer Nyrada so far is this year’s star performer with almost an eightfold gain Diagnostic house Lumos and imagers Artrya and 4D Medical also have run a good race, with their US plans unfolding to script Nyrada ch...

Highlights Market sentiment remains cautious as sector leadership rotates Defensive assets attract attention amid uneven trading conditions Select ASX-listed names experience heightened activity Australian equities are...

The Lynas Rare Earths Ltd (ASX: LYC) share price has seen massive volatility over the last year. In the past 12 months, it's up by almost 90%, as the chart below shows. That compares to a rise of less than 5% for the S&P/ASX 200 Index (...

It was a rough start to the trading week for the S&P/ASX 200 Index (ASX: XJO) and many ASX shares this Monday. After ending the week on a distinct high last Friday, investors were a little less enthused...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a disappointing decline. At the time of writing, the benchmark index is down 0.8% to 8,629.6 points. Four ASX shares that are not letting that hold them back to...

Highlights Market-wide weakness reshapes sector leadership Select defence, healthcare and mining names regain attention Policy shifts and governance reforms redraw expectations Australian shares softened as global sent...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are starting the week strongly. In morning trade, the ASX 200 stock is up 3.5% to $19.59. Why is this ASX 200 stock rising today? Investors have been bidding the pharmaceuticals company's shares...

The Westgold Resources Ltd (ASX: WGX) share price is in focus after the company announced plans to spin out its non-core Reedy and Comet gold projects into a new standalone vehicle, Valiant Gold Limited, with an associated IPO in Q3 FY26. K...

The IperionX Ltd (ASX: IPX) share price is in focus today after the company announced a new project with Carver Pump to accelerate the production of critical titanium components for U.S. Navy ships. The initial purchase order includes proto...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is making headlines today after announcing US FDA approval for DAYBUE STIX, a new powder formulation of trofinetide for Rett syndrome. This milestone gives patients and caregivers more f...

The Fortescue Ltd (ASX: FMG) share price is in focus after announcing its plan to acquire the remaining 64% of Alta Copper Corp for C$139 million, offering shareholders a 50% premium to Alta Copper's recent 30-day VWAP. This strategic move...

Junior biotechnology company Echo IQ Ltd (ASX: EIQ) has lodged a key submission with the US Food & Drug Administration (FDA), which will help pave the way for sales of its heart failure detection software. The artificial intelligence...

The DigiCo Infrastructure REIT (ASX: DGT) share price is in focus today after the company declared a 1H FY26 distribution of 6.0 cents per security, rewarding investors and highlighting progress on its data centre growth plans. What did Dig...

The Treasury Wine Estates Ltd (ASX: TWE) share price was placed in a trading halt today as the company prepares to release a significant announcement and host an investor update session, which will cover its outlook. What did Treasury Wine...

The ASX small-cap stock Kelsian Group Ltd (ASX: KLS) has the potential to deliver very pleasing returns to investors, and I think it's a solid buy for the long-term. The fact that its share price has slipped 18% since 7 October 2025 make...

It was a tough Tuesday for the S&P/ASX 200 Index (ASX: XJO) and many ASX shares today. After a bouncy day, the ASX 200 ended up closing 0.45% lower, probably unassisted by the Reserve Bank of Australia'...

A global study links Alzheimer’s disease with kidney malfunction FDA czar Dr Marty Makary outlines the agency’s priorities Pro Medicus fesses up to a cyber breach   The quest for an Alzheimer’s disease cure has taken a new twist, with an...

Strong clinical data can help biotechs secure lucrative licensing and partnership deals  Dimerix has four licensing deals for lead drug DMX-200 in rare kidney disease Platinum’s Global Health Sciences Fund manager Dr Bianca Ogden notes se...

The S&P/ASX 200 Index (ASX: XJO) ended the trading week on a very hard note indeed, suffering a nasty drop this Friday. By the time trading wrapped up today, the ASX 200 had tumbled a notable 1.36%. T...

Investors in Neuren Pharmaceuticals Ltd (ASX: NEU) have experienced an exhilarating year. The ASX 200 healthcare stock has exploded with over 115% since hitting a 52-week low in April. Stock tipped to rise Analysts at Macquarie Group...

Two dozen esteemed sector figures recently gathered over lunch to recount their career highs and lows One luminary recalls an uncomfortable close encounter with a drug cartel, while others overcame the impact of academic and corporate frau...

It was a sour end to the trading week this Friday, as investors couldn't quite hold onto the optimism that we saw yesterday. By the close of trading, the S&P/ASX 200 Index (ASX: XJO) had sunk by a heft...

ASX health sector down 0.94% for past week, while broader market falls 1.22% Under pressure CSL moves to reassure investors at US Capital Markets Day this week Imricor soars after world’s first VT ablation performed entirely under real-tim...

It has been another busy week for many of Australia's top brokers. This has led to the release of a number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these...

On Thursday, Neuren Pharmaceuticals Ltd (ASX: NEU) shares were sold off and finished the day 10% lower. While this is disappointing for shareholders, the team at Bell Potter thinks that it has created an attractive entry point for investors...

Yesterday afternoon, ASX 200 company GPT Group (ASX: GPT) upgraded its 2025 full-year guidance, buoyed by a strong September quarter. Retail investment portfolio occupancy hit 99.6%, while group-wide weighted average lease expiry (WALE) sto...

The James Hardie Industries (ASX: JHX) share price has come under pressure today, sliding from $29.48 yesterday to a low of $24.41 following a notable spike in trading volume. What did James Hardie Industries report? The JHX share price fe...

Australian biotechs are carving out expanded territory in the US Truscreen edges towards cash flow break even CSL is extracting more blood from donors, more efficiently   Today’s crop of ASX announcements highlights the potential of the U...

With more than seven million users on the HotCopper forums, every discussion and speculation can move Australian markets, which is why getting out in front of those trends is so important for any trader worth their salt. Listen to the Ho...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is in focus today after the company reported record Q3 2025 DAYBUE net sales of US$101.1 million, up 11% from a year earlier, and royalty income of A$16.4 million, up 24% year-on-year. W...

The Vicinity Centres (ASX: VCX) share price is in focus today after the company reported statutory net profit of $1.0 billion for FY25—up from $547.1 million last year. Funds From Operations reached $674 million, with annual distribution...